Table 4

Ingenuity canonical pathways significantly (B-H p-value < 0.05) represented by the genes down-regulated in the common metastatic signature

Ingenuity Canonical Pathways

Fisher Exact

p-value

B-H

p-value

Ratio


Actin Cytoskeleton Signaling

7.94E-08

1.51E-05

4.26E-02

Regulation of Actin-based Motility by Rho

3.89E-06

2.14E-04

6.52E-02

Integrin Signaling

4.57E-06

2.14E-04

3.96E-02

Calcium Signaling

2.24E-05

7.08E-04

3.41E-02

Protein Kinase A Signaling

1.12E-04

3.02E-03

2.51E-02

RhoA Signaling

1.86E-04

4.27E-03

4.55E-02

NRF2-mediated Oxidative Stress Response

2.00E-04

4.27E-03

3.28E-02

ILK Signaling

2.51E-04

4.68E-03

3.23E-02

Thrombin Signaling

3.39E-04

5.75E-03

2.94E-02

Chemokine Signaling

4.17E-04

6.61E-03

5.33E-02

VEGF Signaling

8.32E-04

1.07E-02

4.12E-02

FAK Signaling

8.71E-04

1.07E-02

4.00E-02

Phospholipase C Signaling

9.12E-04

1.07E-02

2.34E-02

cAMP-mediated Signaling

1.02E-03

1.15E-02

3.11E-02

Tight Junction Signaling

1.15E-03

1.20E-02

2.99E-02

Relaxin Signaling

3.47E-03

2.95E-02

2.68E-02

CDK5 Signaling

9.12E-03

6.17E-02

3.19E-02

IL-8 Signaling

9.33E-03

6.17E-02

2.15E-02


B-H: Benjamini-Hochberg method for correcting for the multiple testing problem; Ratio: The number of genes from the metastatic signature that map to the pathway divided by the total number of genes that map to the canonical pathway.

Daves et al. BMC Medical Genomics 2011 4:56   doi:10.1186/1755-8794-4-56

Open Data